BRIEF published on 09/05/2025 at 15:05, 10 months ago Onco-Innovations Appoints Dr. John Mackey to Advisory Board Clinical Trials Oncology John Mackey Onco-Innovations PNKP Inhibitor
BRIEF published on 09/05/2025 at 15:05, 10 months ago Onco-Innovations nomme le Dr John Mackey au conseil consultatif Essais Cliniques John Mackey Oncologie Onco-Innovations Inhibiteur De PNKP
PRESS RELEASE published on 09/05/2025 at 15:00, 10 months ago Onco-Innovations Appoints Dr. John Mackey to Scientific & Clinical Advisory Board Onco-Innovations appoints Dr. John Mackey, expert in oncology and clinical trials, to Scientific & Clinical Advisory Board, enhancing translational research capabilities for PNKP inhibitor program Clinical Trials Oncology Onco-Innovations PNKP Inhibitor Dr. John Mackey
BRIEF published on 08/15/2025 at 15:20, 10 months 21 days ago Onco-Innovations Achieves High Warrant Exercise Rate Warrants Non-dilutive Financing Cancer Research Shareholder Confidence Capital Strategy
BRIEF published on 08/15/2025 at 15:20, 10 months 21 days ago Onco-Innovations atteint un taux d'exercice de mandat élevé Financement Non Dilutif Confiance Des Actionnaires Mandats Stratégie De Capital Recherche Sur Le Cancer
PRESS RELEASE published on 08/15/2025 at 15:15, 10 months 21 days ago Onco-Innovations Announces 90% of $0.60 Warrants Have Been Exercised Onco-Innovations announces successful execution of key capital strategy with over 90% of outstanding warrants exercised at $0.60, reinforcing investor confidence and internal financing effectiveness Warrants Investor Confidence Capital Strategy Onco-Innovations Internal Financing
BRIEF published on 08/13/2025 at 23:05, 10 months 23 days ago Onco-Innovations Closes $400,000 Private Placement Private Placement Securities Regulation Shares And Warrants Onco-Innovations Funding And Development
BRIEF published on 08/13/2025 at 23:05, 10 months 23 days ago Onco-Innovations clôture un placement privé de 400 000 $ Placement Privé Réglementation Des Valeurs Mobilières Actions Et Bons De Souscription Onco-Innovations Financement Et Développement
PRESS RELEASE published on 08/13/2025 at 23:00, 10 months 23 days ago Onco-Innovations Announces Closing of Private Placement Onco-Innovations Limited announces the closing of a non-brokered private placement, raising $400,000 for general corporate purposes and cancer research. Statutory hold period applies. Not for distribution in the US Non-brokered Private Placement Cancer Research Statutory Hold Period Onco-Innovations Limited Not For Distribution
BRIEF published on 08/04/2025 at 22:10, 11 months 1 day ago Onco-Innovations Sets Course for Human Trials with Avance Clinical Agreement Clinical Trial Onco-Innovations PNKP Inhibitor Avance Clinical Regulatory Preparations
Published on 07/06/2026 at 02:25, 38 minutes ago Tunkillia Infill Drilling Delivers More High-Grade Assays
Published on 07/03/2026 at 23:00, 2 days 4 hours ago Eagle Plains Partner Refined Energy Announces Final Results for Winter 2026 Drill Program at Dufferin West
Published on 07/03/2026 at 21:28, 2 days 5 hours ago Trifecta Gold Announces Closing of $1.66 Million Private Placement
Published on 07/03/2026 at 19:30, 2 days 7 hours ago Polaris Renewable Energy Announces Q2 2026 Investor Call Details
Published on 07/06/2026 at 02:33, 30 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Portfolio valuations update
Published on 07/05/2026 at 13:45, 13 hours 18 minutes ago XPPen renforce son engagement en faveur de l’animation grâce à son partenariat avec la Résidence du Festival d’Annecy 2026 et sa présence au MIFA
Published on 07/05/2026 at 13:45, 13 hours 18 minutes ago XPPen Strengthens Its Commitment to Animation with 2026 Annecy Festival Residency Partnership and MIFA Showcase
Published on 07/04/2026 at 17:35, 1 day 9 hours ago Vantage Introduces 24/7 Gold CFD Trading with XAUUSD247
Published on 07/03/2026 at 21:49, 2 days 5 hours ago Safran annonce la fin des négociations concernant le projet d'acquisition d’Exail Technologies.
Published on 07/03/2026 at 21:49, 2 days 5 hours ago Safran announces the end of negotiations regarding the contemplated acquisition of Exail Technologies.
Published on 07/03/2026 at 18:42, 2 days 8 hours ago Total number of voting rights and shares making up the share capital at June 30, 2026
Published on 07/03/2026 at 18:36, 2 days 8 hours ago Disclosure of transactions in own shares from July 1 to July 3, 2026
